Understanding Myopia Management Options: Atropine

Ultimately, the prescribed dosage selected should be patient-driven and can be amended if progression is noted or side effects are bothersome

By: Patricia Fulmer, OD, FAAO

Optometric Management December 1, 2025

Clinical Report: Understanding Myopia Management Options: Atropine

Overview

Revise to clarify that the 0.05% concentration is preferred due to better outcomes and minimal side effects.

Background

Myopia management is crucial for mitigating visual impairment and associated disease risks in children. Atropine has been utilized for decades, but recent studies have focused on lower dosages to reduce side effects while maintaining efficacy. Understanding the appropriate use of atropine is essential for eye care practitioners in managing pediatric myopia effectively.

Data Highlights

No numerical data available in the source material.

Key Findings

Low-dose atropine (0.01% and 0.05%) has shown efficacy in controlling myopia progression.
The 0.05% concentration is favored for initial treatment due to better outcomes and fewer side effects.
Atropine should be administered once nightly, with ongoing monitoring for visual discomfort in children.
Currently, there are no FDA-approved low-dose atropine drops in the U.S.; compounding is necessary.
Combination therapies with atropine and other modalities are being explored for enhanced myopia control.

Clinical Implications

Highlight the importance of patient-driven dosage adjustments based on side effects.

Conclusion

Low-dose atropine represents a promising strategy in myopia management, balancing efficacy with tolerability. Continued research and clinical practice will refine its application in pediatric populations.

PentaVision

Optometric Management